Classification Term: 2201

Gamma amino acids and derivatives (ontology term: CHEMONTID:0001880)

Amino acids having a (-NH2) group attached to the gamma carbon atom." []

found 60 associated metabolites at family metabolite taxonomy ontology rank level.

Ancestor: Amino acids and derivatives

Child Taxonomies: There is no child term of current ontology term.

4-Acetamidobutanoate

N-Acetyl-gamma-amino-N-butyric acid

C6H11NO3 (145.0739)


4-Acetamidobutanoic acid, also known as 4-acetamidobutanoate or N-acetyl-4-aminobutyric acid, is a member of the class of compounds known as gamma amino acids and derivatives. These compounds are amino acids having an -NH2 group attached to the gamma carbon atom. 4-Acetamidobutanoic acid is soluble in water. 4-Acetamidobutanoic acid can be found in a number of food items such as Rubus species (blackberry, raspberry), cassava, pepper (Capsicum frutescens), and napa cabbage, which makes 4-acetamidobutanoic acid a potential biomarker for the consumption of these food products. 4-Acetamidobutanoic acid can be found in blood, feces, and urine, as well as in human prostate tissue. 4-Acetamidobutanoic acid exists in all eukaryotes, ranging from yeast to humans. 4-Acetamidobutanoic acid is a GABA derivative, a product of the urea cycle and the metabolism of amino groups, and the product of NAD-linked aldehyde dehydrogenase (EC 1.2.1.3) (KEGG). 4-Acetamidobutanoic acid is a GABA derivative, product of the Urea cycle and metabolism of amino groups, the product of NAD-linked aldehyde dehydrogenase (EC 1.2.1.3) (KEGG) [HMDB]. 4-Acetamidobutanoic acid is found in many foods, some of which are custard apple, japanese walnut, shiitake, and oxheart cabbage. 4-Acetamidobutanoic acid (N-acetyl GABA), the main metabolite of GABA, exhibits antioxidant and antibacterial activities[1]. 4-Acetamidobutanoic acid (N-acetyl GABA), the main metabolite of GABA, exhibits antioxidant and antibacterial activities[1]. 4-Acetamidobutanoic acid (N-acetyl GABA), the main metabolite of GABA, exhibits antioxidant and antibacterial activities[1].

   

4-Guanidinobutanoic acid

4-[(diaminomethylidene)amino]butanoic acid

C5H11N3O2 (145.0851)


4-Guanidinobutanoic acid, also known as gamma-guanidinobutyrate or 4-(carbamimidamido)butanoate, belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom. 4-Guanidinobutanoic acid is a normal metabolite present in low concentrations. 4-Guanidinobutanoic acid exists in all eukaryotes, ranging from yeast to humans. Outside of the human body, 4-Guanidinobutanoic acid has been detected, but not quantified in a few different foods, such as apples, french plantains, and loquats. This could make 4-guanidinobutanoic acid a potential biomarker for the consumption of these foods. Patients with hyperargininemia have an arginase deficiency which leads to blockade of the urea cycle in the last step with several clinical symptoms. Owing to the arginase deficiency this patients accumulate arginine which leads eventually to epileptogenic guanidino compounds (PMID 7752905). 4-guanidinobutanoic acid, also known as gamma-guanidinobutyrate or 4-(carbamimidamido)butanoate, belongs to gamma amino acids and derivatives class of compounds. Those are amino acids having a (-NH2) group attached to the gamma carbon atom. 4-guanidinobutanoic acid is slightly soluble (in water) and a weakly acidic compound (based on its pKa). 4-guanidinobutanoic acid can be found in apple, french plantain, and loquat, which makes 4-guanidinobutanoic acid a potential biomarker for the consumption of these food products. 4-guanidinobutanoic acid can be found primarily in blood, cerebrospinal fluid (CSF), and urine, as well as in human prostate tissue. 4-guanidinobutanoic acid exists in all eukaryotes, ranging from yeast to humans. Moreover, 4-guanidinobutanoic acid is found to be associated with cirrhosis. CONFIDENCE standard compound; ML_ID 15 KEIO_ID G032 4-Guanidinobutanoic acid is a normal metabolite present in low concentrations. 4-Guanidinobutanoic acid is a normal metabolite present in low concentrations.

   

Baclofen

beta-(Aminomethyl)-4-chlorobenzenepropanoic acid

C10H12ClNO2 (213.0557)


Baclofen is a gamma-amino-butyric acid (GABA) derivative used as a skeletal muscle relaxant. Baclofen stimulates GABA-B receptors leading to decreased frequency and amplitude of muscle spasms. It is especially useful in treating muscle spasticity associated with spinal cord injury. It appears to act primarily at the spinal cord level by inhibiting spinal polysynaptic afferent pathways and, to a lesser extent, monosynaptic afferent pathways. M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018755 - GABA Agonists D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant D002491 - Central Nervous System Agents (R)-Baclofen (Arbaclofen) is a selective GABAB receptor agonist[1]. Baclofen, a lipophilic derivative of γ-aminobutyric acid (GABA), is an orally active, selective metabotropic GABAB receptor (GABABR) agonist. Baclofen mimics the action of GABA and produces slow presynaptic inhibition through the GABAB receptor. Baclofen has high blood brain barrier penetrance. Baclofen has the potential for muscle spasticity research[1][2][3].

   

Doxorubicin

(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione

C27H29NO11 (543.1741)


Doxorubicin is only found in individuals that have used or taken this drug. It is antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of daunorubicin. [PubChem]Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors KEIO_ID D064

   

Gabapentin

2-[1-(aminomethyl)cyclohexyl]acetic acid

C9H17NO2 (171.1259)


Gabapentin was originally developed as a chemical analogue of gamma-aminobutyric acid (GABA) to reduce the spinal reflex for the treatment of spasticity and was found to have anticonvulsant activity in various seizure models. In addition, it also displays antinociceptive activity in various animal pain models. Clinically, gabapentin is indicated as an add-on medication for the treatment of partial seizures, and neuropathic pain. It was also claimed to be beneficial in several other clinical disorders such as anxiety, bipolar disorder, and hot flashes. The possible mechanisms or targets involved in the multiple therapeutic actions of gabapentin have been actively studied. Since gabapentin was developed, several hypotheses had been proposed for its action mechanisms. They include selectively activating the heterodimeric GABA(B) receptors consisting of GABA(B1a) and GABA(B2) subunits, selectively enhancing the NMDA current at GABAergic interneurons, or blocking AMPA-receptor-mediated transmission in the spinal cord, binding to the L-alpha-amino acid transporter, activating ATP-sensitive K(+) channels, activating hyperpolarization-activated cation channels, and modulating Ca(2+) current by selectively binding to the specific binding site of [(3)H]gabapentin, the alpha(2)delta subunit of voltage-dependent Ca(2+) channels. Different mechanisms might be involved in different therapeutic actions of gabapentin. In this review, we summarized the recent progress in the findings proposed for the antinociceptive action mechanisms of gabapentin and suggest that the alpha(2)delta subunit of spinal N-type Ca(2+) channels is very likely the analgesic action target of gabapentin. (PMID: 16474201) [HMDB] Gabapentin was originally developed as a chemical analogue of gamma-aminobutyric acid (GABA) to reduce the spinal reflex for the treatment of spasticity and was found to have anticonvulsant activity in various seizure models. In addition, it also displays antinociceptive activity in various animal pain models. Clinically, gabapentin is indicated as an add-on medication for the treatment of partial seizures, and neuropathic pain. It was also claimed to be beneficial in several other clinical disorders such as anxiety, bipolar disorder, and hot flashes. The possible mechanisms or targets involved in the multiple therapeutic actions of gabapentin have been actively studied. Since gabapentin was developed, several hypotheses had been proposed for its action mechanisms. They include selectively activating the heterodimeric GABA(B) receptors consisting of GABA(B1a) and GABA(B2) subunits, selectively enhancing the NMDA current at GABAergic interneurons, or blocking AMPA-receptor-mediated transmission in the spinal cord, binding to the L-alpha-amino acid transporter, activating ATP-sensitive K(+) channels, activating hyperpolarization-activated cation channels, and modulating Ca(2+) current by selectively binding to the specific binding site of [(3)H]gabapentin, the alpha(2)delta subunit of voltage-dependent Ca(2+) channels. Different mechanisms might be involved in different therapeutic actions of gabapentin. In this review, we summarized the recent progress in the findings proposed for the antinociceptive action mechanisms of gabapentin and suggest that the alpha(2)delta subunit of spinal N-type Ca(2+) channels is very likely the analgesic action target of gabapentin. (PMID: 16474201). D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D018692 - Antimanic Agents N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BF - Gabapentinoids D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Oseltamivir

Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid

C16H28N2O4 (312.2049)


Oseltamivir is only found in individuals that have used or taken this drug. It is an acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. [PubChem]Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AH - Neuraminidase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 658 CONFIDENCE standard compound; INTERNAL_ID 2068 D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Vigabatrin

Acid, gamma-vinyl-gamma-aminobutyric

C6H11NO2 (129.079)


Vigabatrin is only found in individuals that have used or taken this drug. It is an analogue of gamma-aminobutyric acid. It is an irreversible inhibitor of 4-aminobutyrate transaminase, the enzyme responsible for the catabolism of gamma-aminobutyric acid. (From Martindale The Extra Pharmacopoeia, 31st ed)It is believed that vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase GABA-T) or block the reuptake of GABA into glia and nerve endings. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AG - Fatty acid derivatives C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D018377 - Neurotransmitter Agents > D018682 - GABA Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3626 D004791 - Enzyme Inhibitors Vigabatrin (γ-Vinyl-GABA), an inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase[1][2][3].

   

γ-Aminobutyric acid

gamma-Aminobutyric acid, calcium salt (2:1)

C4H9NO2 (103.0633)


gamma-Aminobutyric acid (GABA) is an inhibitory neurotransmitter found in the nervous systems of widely divergent species, including humans. It is the chief inhibitory neurotransmitter in the vertebrate central nervous system. In vertebrates, GABA acts at inhibitory synapses in the brain. It acts by binding to specific transmembrane receptors in the plasma membrane of both pre- and postsynaptic neurons. This binding causes the opening of ion channels to allow either the flow of negatively-charged chloride ions into the cell or positively-charged potassium ions out of the cell. This will typically result in a negative change in the transmembrane potential, usually causing hyperpolarization. Three general classes of GABA receptor are known (PMID: 10561820). These include GABA-A and GABA-C ionotropic receptors, which are ion channels themselves, and GABA-B metabotropic receptors, which are G protein-coupled receptors that open ion channels via intermediaries known as G proteins (PMID: 10561820). Activation of the GABA-B receptor by GABA causes neuronal membrane hyperpolarization and a resultant inhibition of neurotransmitter release. In addition to binding sites for GABA, the GABA-A receptor has binding sites for benzodiazepines, barbiturates, and neurosteroids. GABA-A receptors are coupled to chloride ion channels. Therefore, activation of the GABA-A receptor induces increased inward chloride ion flux, resulting in membrane hyperpolarization and neuronal inhibition (PMID: 10561820). After release into the synapse, free GABA that does not bind to either the GABA-A or GABA-B receptor complexes can be taken up by neurons and glial cells. Four different GABA membrane transporter proteins (GAT-1, GAT-2, GAT-3, and BGT-1), which differ in their distribution in the CNS, are believed to mediate the uptake of synaptic GABA into neurons and glial cells. The GABA-A receptor subtype regulates neuronal excitability and rapid changes in fear arousal, such as anxiety, panic, and the acute stress response (PMID: 10561820). Drugs that stimulate GABA-A receptors, such as the benzodiazepines and barbiturates, have anxiolytic and anti-seizure effects via GABA-A-mediated reduction of neuronal excitability, which effectively raises the seizure threshold. GABA-A antagonists produce convulsions in animals and there is decreased GABA-A receptor binding in a positron emission tomography (PET) study of patients with panic disorder. Neurons that produce GABA as their output are called GABAergic neurons and have chiefly inhibitory action at receptors in the vertebrate. Medium spiny neurons (MSNs) are a typical example of inhibitory CNS GABAergic cells. GABA has been shown to have excitatory roles in the vertebrate, most notably in the developing cortex. Organisms synthesize GABA from glutamate using the enzyme L-glutamic acid decarboxylase and pyridoxal phosphate as a cofactor (PMID: 12467378). It is worth noting that this involves converting the principal excitatory neurotransmitter (glutamate) into the principal inhibitory one (GABA). Drugs that act as agonists of GABA receptors (known as GABA analogs or GABAergic drugs), or increase the available amount of GABA typically have relaxing, anti-anxiety, and anti-convulsive effects. GABA is found to be deficient in cerebrospinal fluid and the brain in many studies of experimental and human epilepsy. Benzodiazepines (such as Valium) are useful in status epilepticus because they act on GABA receptors. GABA increases in the brain after administration of many seizure medications. Hence, GABA is clearly an antiepileptic nutrient. Inhibitors of GAM metabolism can also produce convulsions. Spasticity and involuntary movement syndromes, such as Parkinsons, Friedreichs ataxia, tardive dyskinesia, and Huntingtons chorea, are all marked by low GABA when amino acid levels are studied. Trials of 2 to 3 g of GABA given orally have been effective in various epilepsy and spasticity syndromes. Agents that elevate GABA are als... Gamma-aminobutyric acid, also known as gaba or 4-aminobutanoic acid, belongs to gamma amino acids and derivatives class of compounds. Those are amino acids having a (-NH2) group attached to the gamma carbon atom. Thus, gamma-aminobutyric acid is considered to be a fatty acid lipid molecule. Gamma-aminobutyric acid is soluble (in water) and a weakly acidic compound (based on its pKa). Gamma-aminobutyric acid can be synthesized from butyric acid. Gamma-aminobutyric acid is also a parent compound for other transformation products, including but not limited to, (1S,2S,5S)-2-(4-glutaridylbenzyl)-5-phenylcyclohexan-1-ol, 4-(methylamino)butyric acid, and pregabalin. Gamma-aminobutyric acid can be found in a number of food items such as watercress, sour cherry, peach, and cardoon, which makes gamma-aminobutyric acid a potential biomarker for the consumption of these food products. Gamma-aminobutyric acid can be found primarily in most biofluids, including urine, cerebrospinal fluid (CSF), blood, and feces, as well as throughout most human tissues. Gamma-aminobutyric acid exists in all living species, ranging from bacteria to humans. In humans, gamma-aminobutyric acid is involved in a couple of metabolic pathways, which include glutamate metabolism and homocarnosinosis. Gamma-aminobutyric acid is also involved in few metabolic disorders, which include 2-hydroxyglutric aciduria (D and L form), 4-hydroxybutyric aciduria/succinic semialdehyde dehydrogenase deficiency, hyperinsulinism-hyperammonemia syndrome, and succinic semialdehyde dehydrogenase deficiency. Moreover, gamma-aminobutyric acid is found to be associated with alzheimers disease, hyper beta-alaninemia, tuberculous meningitis, and hepatic encephalopathy. Gamma-aminobutyric acid is a non-carcinogenic (not listed by IARC) potentially toxic compound. gamma-Aminobutyric acid (γ-Aminobutyric acid) (GABA ) is the chief inhibitory neurotransmitter in the mammalian central nervous system. Its principal role is reducing neuronal excitability throughout the nervous system. In humans, GABA is also directly responsible for the regulation of muscle tone . Chronically high levels of GABA are associated with at least 5 inborn errors of metabolism including: D-2-Hydroxyglutaric Aciduria, 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency, GABA-Transaminase Deficiency, Homocarnosinosis and Succinic semialdehyde dehydrogenase deficiency (T3DB). [Spectral] 4-Aminobutanoate (exact mass = 103.06333) and D-2-Aminobutyrate (exact mass = 103.06333) were not completely separated on HPLC under the present analytical conditions as described in AC$XXX. Additionally some of the peaks in this data contains dimers and other unidentified ions. Acquisition and generation of the data is financially supported in part by CREST/JST. COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018377 - Neurotransmitter Agents > D018682 - GABA Agents KEIO_ID A002 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS γ-Aminobutyric acid (4-Aminobutyric acid) is a major inhibitory neurotransmitter in the adult mammalian brain, binding to the ionotropic GABA receptors (GABAA receptors) and metabotropic receptors (GABAB receptors. γ-Aminobutyric acid shows calming effect by blocking specific signals of central nervous system[1][2]. γ-Aminobutyric acid (4-Aminobutyric acid) is a major inhibitory neurotransmitter in the adult mammalian brain, binding to the ionotropic GABA receptors (GABAA receptors) and metabotropic receptors (GABAB receptors. γ-Aminobutyric acid shows calming effect by blocking specific signals of central nervous system[1][2]. γ-Aminobutyric acid (4-Aminobutyric acid) is a major inhibitory neurotransmitter in the adult mammalian brain, binding to the ionotropic GABA receptors (GABAA receptors) and metabotropic receptors (GABAB receptors. γ-Aminobutyric acid shows calming effect by blocking specific signals of central nervous system[1][2].

   

4-Amino-3-hydroxybutyrate

4-Amino-3-hydroxybutyric acid, (Z)-2-butenedioate salt (2:1), (+-)-isomer

C4H9NO3 (119.0582)


4-Amino-3-hydroxybutyrate belongs to the class of organic compounds known as hydroxy fatty acids. These are fatty acids in which the chain bears a hydroxyl group.

   

3-Amino-2,3-dihydrobenzoic acid

5-Amino-1,3-cyclohexadiene-1-carboxylic acid

C7H9NO2 (139.0633)


D004791 - Enzyme Inhibitors

   

2'-Deoxymugineic acid

1-{3-carboxy-3-[(3-carboxy-3-hydroxypropyl)amino]propyl}azetidine-2-carboxylic acid

C12H20N2O7 (304.127)


Isolated from wheat (Triticum aestivum). 2-Deoxymugineic acid is found in many foods, some of which are pot marjoram, kumquat, ginger, and pineappple sage. 2-Deoxymugineic acid is found in cereals and cereal products. 2-Deoxymugineic acid is isolated from wheat (Triticum aestivum).

   

Isomugineic acid

1-{3-carboxy-3-[(3-carboxy-3-hydroxypropyl)amino]-2-hydroxypropyl}azetidine-2-carboxylic acid

C12H20N2O8 (320.122)


Mugineic acid is found in barley. Excreted from the roots of barley (Hordeum vulgare), also in root-washings of oat and ric Isolated from roots of barley (Hordeum vulgare). Isomugineic acid is found in barley and cereals and cereal products.

   

Pregabalin

(3S)-3-(aminomethyl)-5-methylhexanoic acid

C8H17NO2 (159.1259)


Pregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica. It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S. [Wikipedia] D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BF - Gabapentinoids D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

Avenic acid B

4-[(1-carboxy-3-hydroxypropyl)amino]-2-hydroxybutanoic acid

C8H15NO6 (221.0899)


Avenic acid B is found in cereals and cereal products. Avenic acid B is a constituent of the roots of Avena sativa (oats). Constituent of the roots of Avena sativa (oats). Avenic acid B is found in oat and cereals and cereal products.

   

4-Amino-2-methylenebutanoic acid

4-amino-2-methylidenebutanoic acid

C5H9NO2 (115.0633)


4-Amino-2-methylenebutanoic acid is found in nuts. 4-Amino-2-methylenebutanoic acid is found in Arachis hypogaea (peanut

   

Avenic acid A

4-({1-carboxy-3-[(1-carboxy-3-hydroxypropyl)amino]propyl}amino)-2-hydroxybutanoic acid

C12H22N2O8 (322.1376)


Avenic acid A is found in cereals and cereal products. Avenic acid A is isolated from root washings of Avena sativa (oats Isolated from root washings of Avena sativa (oats). Avenic acid A is found in oat and cereals and cereal products.

   

Distichonic acid A

2-[(3-carboxy-3-hydroxypropyl)amino]-4-[(carboxymethyl)amino]-3-hydroxybutanoic acid

C10H18N2O8 (294.1063)


Distichonic acid A is found in cereals and cereal products. Distichonic acid A is produced by Hordeum vulgare (barley). Production by Hordeum vulgare (barley). Distichonic acid A is found in barley and cereals and cereal products.

   

N-Arachidonoyl GABA

4-{[(8Z,11Z,14Z)-1-hydroxyicosa-5,8,11,14-tetraen-1-ylidene]amino}butanoic acid

C24H39NO3 (389.293)


N-Arachidonoyl GABA is also known as N-Arachidonoyl-g-aminobutanoate or Elmiric acid. N-Arachidonoyl GABA is considered to be practically insoluble (in water) and acidic. N-Arachidonoyl GABA is a fatty amide lipid molecule

   

Carboxyethyl-GABA

2-Carboxyethyl gamma-aminobutyric acid

C7H13NO4 (175.0845)


Induces formation of Epstein Barr Virus lymphocytes immediately following infection. (282990) [HMDB] Induces formation of Epstein Barr Virus lymphocytes immediately following infection. (282990).

   

Isoputreanine

N-(3-Aminopropyl)-4-aminobutanoic acid

C7H16N2O2 (160.1212)


Isoputreanine is urinary metabolite of spermidine, which is predominantly excreted as the monoacetyl conjugate of N-(3-aminopropyl)pyrrolidin-2-one, the acetylated γ-lactam form of isoputreanine. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

D-1-[(3-Carboxypropyl)amino]-1-deoxyfructose

4-({[(2R,3S,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl}amino)butanoic acid

C10H19NO7 (265.1161)


D-1-[(3-Carboxypropyl)amino]-1-deoxyfructose is found in fruits. D-1-[(3-Carboxypropyl)amino]-1-deoxyfructose is isolated from stored apricots and peaches. Isolated from stored apricots and peaches. D-1-[(3-Carboxypropyl)amino]-1-deoxyfructose is found in fruits.

   

Distichonic acid B

4-({1-carboxy-3-[(carboxymethyl)amino]-3-hydroxypropyl}amino)-2-hydroxybutanoic acid

C10H18N2O8 (294.1063)


Distichonic acid B is found in cereals and cereal products. Distichonic acid B is from Hordeum vulgare (barley). From Hordeum vulgare (barley). Distichonic acid B is found in barley and cereals and cereal products.

   

mono-isopropyl-disopyramide

2-phenyl-4-[(propan-2-yl)amino]-2-(pyridin-2-yl)butanimidic acid

C18H23N3O (297.1841)


mono-isopropyl-disopyramide is a metabolite of disopyramide. Disopyramide (trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of Ventricular Tachycardia. It is a sodium channel blocker and therefor classified as a Class 1a anti-arrhythmic agent. ’ Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. (Wikipedia) D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics

   

N-Docosahexaenoyl GABA

4-{[(7Z,10Z,13Z,16Z,19Z)-1-hydroxydocosa-4,7,10,13,16,19-hexaen-1-ylidene]amino}butanoic acid

C26H39NO3 (413.293)


N-Docosahexaenoyl GABA is considered to be practically insoluble (in water) and acidic. N-Docosahexaenoyl GABA is a fatty amide lipid molecule

   

N-Linoleoyl GABA

4-{[(9Z,12Z)-1-hydroxyoctadeca-9,12-dien-1-ylidene]amino}butanoic acid

C22H39NO3 (365.293)


N-Linoleoyl GABA is also known as GABA linoleamide or Gabalid. N-Linoleoyl GABA is considered to be practically insoluble (in water) and acidic

   

N-Oleoyl GABA

4-{[(9Z)-1-hydroxyoctadec-9-en-1-ylidene]amino}butanoic acid

C22H41NO3 (367.3086)


N-Oleoyl GABA is considered to be practically insoluble (in water) and acidic. N-Oleoyl GABA is a fatty amide lipid molecule

   

N-Palmitoyl GABA

4-[(1-hydroxyhexadecylidene)amino]butanoic acid

C20H39NO3 (341.293)


N-Palmitoyl GABA is also known as 4-hexadecanoylamino-Butyric acid. N-Palmitoyl GABA is considered to be practically insoluble (in water) and acidic. N-Palmitoyl GABA is a fatty amide lipid molecule

   

N-Stearoyl GABA

4-[(1-hydroxyoctadecylidene)amino]butanoic acid

C22H43NO3 (369.3243)


N-Stearoyl GABA is also known as GABA-steatamide. N-Stearoyl GABA is considered to be practically insoluble (in water) and acidic. N-Stearoyl GABA is a fatty amide lipid molecule

   

N-Acetylisoputreanine

4-({3-[(1-hydroxyethylidene)amino]propyl}amino)butanoic acid

C9H18N2O3 (202.1317)


N-acetylisoputreanine is classified as a gamma amino acid or a Gamma amino acid derivative. Gamma amino acids are amino acids having a (-NH2) group attached to the gamma carbon atom. N-acetylisoputreanine is considered to be a slightly soluble (in water) and a weak acidic compound. N-acetylisoputreanine can be found in humans.

   

(1S,2S,3S,4R)-3-(1-Acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid

4-[(diaminomethylidene)amino]-3-(1-acetamido-2-ethylbutyl)-2-hydroxycyclopentane-1-carboxylic acid

C15H28N4O4 (328.211)


   

1-(3-Carboxypropylcarbamoyl)-5-fluorouracil

4-[(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-1-carbonyl)amino]butanoic acid

C9H10FN3O5 (259.0604)


   

2-Aminobenzylstatine

4-{[(2-aminophenyl)methyl]amino}-3-hydroxy-6-methylheptanoic acid

C15H24N2O3 (280.1787)


   

3-(Aminomethyl)-5-methylhexanoic acid

(S)-3-(Aminomethyl)-5-methylhexanoic acid

C8H17NO2 (159.1259)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

2-((3-Carboxypropyl)carbamoyl)benzoic acid

2-[(3-carboxypropyl)carbamoyl]benzoic acid

C12H13NO5 (251.0794)


   

4-[(2,4-Dihydroxy-3,3-dimethylbutanoyl)amino]butanoic acid

4-(2,4-dihydroxy-3,3-dimethylbutanamido)butanoic acid

C10H19NO5 (233.1263)


D002491 - Central Nervous System Agents > D018697 - Nootropic Agents

   

4-Amino-3-phenylbutanoic acid

4-Amino-3-phenylbutyric acid, (DL)-(+-)-mixture

C10H13NO2 (179.0946)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D003292 - Convulsants N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018755 - GABA Agonists D002491 - Central Nervous System Agents > D000927 - Anticonvulsants

   

4-Amino-5-oxo-pentanoic acid

4-AMINO-5-OXO-PENTANOIC ACID

C5H9NO3 (131.0582)


   

Pivagabine

4-[(1-hydroxy-2,2-dimethylpropylidene)amino]butanoic acid

C9H17NO3 (187.1208)


   

2-Naphthylaminomethyl-gamma-aminobutyric acid

4-({[(naphthalen-2-yl)amino]methyl}amino)butanoic acid

C15H18N2O2 (258.1368)


   

4-((6-Methoxyquinolin-8-yl)amino)pentanoic acid

8-(3-Carboxy-1-methylpropylamino)-6-methoxyquinoline

C15H18N2O3 (274.1317)


   

gamma-Aminobutyric acid cetyl ester

gamma-Aminobutyric acid cetyl ester hydrochloride

C20H41NO2 (327.3137)


   

Edoxaban

N-(5-chloropyridin-2-yl)-N-[4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide

C24H30ClN7O4S (547.1768)


   

epsilon-(Carboxyethyl)lysine

2,6-diaminononanedioic acid

C9H18N2O4 (218.1267)


   

Gabapentin enacarbil

2-(1-{[({1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl)amino]methyl}cyclohexyl)acetic acid

C16H27NO6 (329.1838)


C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic

   

4-Aminohex-5-ynoic acid

4-Amino-5-hexynoic acid

C6H9NO2 (127.0633)


D004791 - Enzyme Inhibitors

   

cis-N-((4-Cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide

N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexane-1-carboxamide

C21H24F3N7O (447.1994)


   

Mirogabalin

2-[6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid

C12H19NO2 (209.1416)


   

N-[1'-(Aminocarbonyl)-2',2'-dimethylpropyl]-1-(cyclohexylmethyl)-1h-indazole-3-carboxamide

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

C21H30N4O2 (370.2369)


   

N-Desisopropyl Pentisomide

4-Methyl-2-{2-[(propan-2-yl)amino]ethyl}-2-(pyridin-2-yl)pentanimidate

C16H27N3O (277.2154)


   

Platyconic acid A

8a-({[3-({5-[(4-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl)oxy]-3,4-dihydroxy-6-methyloxan-2-yl}oxy)-4,5-dihydroxyoxan-2-yl]oxy}carbonyl)-2,8-dihydroxy-4-(hydroxymethyl)-6a,6b,11,11,14b-pentamethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid

C57H90O29 (1238.5567)


   

Plazomicin

4-Amino-N-{5-amino-4-[(3-amino-6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2H-pyran-2-yl)oxy]-2-{[3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy}-3-hydroxycyclohexyl}-2-hydroxybutanimidate

C25H48N6O10 (592.3432)


   

4-Amino-5-oxopentanamide

4-Amino-5-oxopentanimidate

C5H10N2O2 (130.0742)


   

sPLA2 inhibitor

5-[4-(Benzyloxy)phenyl]-4-[(1-hydroxy-7-phenylheptylidene)amino]pentanoate

C31H37NO4 (487.2722)


   

Statine

4-Amino-3-hydroxy-6-methylheptanoic acid

C8H17NO3 (175.1208)


   

Tryptoquivaline

1-(3-{1-hydroxy-2,2-dimethyl-3,5-dioxo-1,2,3,9a-tetrahydrospiro[imidazolidino[1,2-a]indole-9,2-oxolane]-4-yl}-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl acetate

C29H30N4O7 (546.2114)


   

TS-943

4-({amino[4-({5-[(2-carboxyethyl)-C-hydroxycarbonimidoyl]-3,4-dimethyl-2,3-dihydro-1,3-thiazol-2-ylidene}carbamoyl)phenyl]methylidene}amino)butanoate

C21H25N5O6S (475.1525)


   

(4S)-4-Amino-1,3-dioxohexane-1,2,6-tricarboxylic acid

4-amino-1,3-dioxohexane-1,2,6-tricarboxylic acid

C9H11NO8 (261.0485)


   

gamma-Aminobutyric acid-betaxanthin

(2S,4E)-4-[(2Z)-2-[(3-carboxypropyl)imino]ethylidene]-1,2,3,4-tetrahydropyridine-2,6-dicarboxylic acid

C13H16N2O6 (296.1008)


   

Lusutrombopag

(2E)-3-{2,6-dichloro-4-[(4-{3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-2-enoic acid

C29H32Cl2N2O5S (590.1409)


B - Blood and blood forming organs > B02 - Antihemorrhagics > B02B - Vitamin k and other hemostatics C78275 - Agent Affecting Blood or Body Fluid

   

Elagolix Sodium

4-{[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl]-1-phenylethyl]amino}butanoic acid

C32H30F5N3O5 (631.2106)